Dow Jones
39.431,51 -81,29 (-0,21%) Nasdaq
16.388,24 +47,34 (+0,29%) Nikkei 225
38.407,78 +228,32 (+0,60%) EUR/USD
1,0790 -0,0003 (-0,03%) Bitcoin EUR
58.480,33 +1.361,59 (+2,38%) CMC Crypto 200
1.293,52 +33,32 (+2,64%)
Nexalin Technology, Inc. (NXL)
Dopo ore:
| Chiusura precedente | 1,2800 |
| Aperto | 1,2600 |
| Denaro | 1,1800 x 100 |
| Lettera | 1,2600 x 100 |
| Min-Max giorno | 1,1900 - 1,2800 |
| Intervallo di 52 settimane | 0,2530 - 3,4000 |
| Volume | |
| Media Volume | 848.734 |
| Capitalizzazione | 9,206M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,6300 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
Study reveals that Nexalin’s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health diseaseHOUSTON, TX, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the publication of a research article titled, “Evidence of a large current of transcranial alternating current stimulation directly to deep brai
GlobeNewswireNexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
New migraine data builds on prior clinical studies in depression Migraine trial results Migraine trial results Depression trial results Depression trial results HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA) neurostimulation device, including the results of a study in p
- GlobeNewswire
Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participating in a live interview with the “Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio show today, Thursday, August 3rd, 2023 at 3:00 PM ET. Mark White, CEO of Nexalin Technology, Inc., stated, “I am very excited to discuss recent developments and upcoming milestones regarding our n
